medRxiv is receiving many new papers on coronavirus SARS-CoV-2.   A reminder: these are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information.

This channel curates preprints specific to quantitative methods in pre-clinical and clinical drug development, the approval and post-marketing phases, and clinical therapeutics. The papers can range in varying topics in this discipline:

  • Clinical Pharmacology and Therapeutics (#cpt)
  • Therapeutic Drug Monitoring (#tdm)
  • Pharmacometrics (#phmx)
  • Quantitative Systems Pharmacology (#qsp)
  • Clinical Trial Design/Optimal Design (#ctd, #od)
  • Pharmacoeconomics (#pec)
  • Meta analyses (#metanal)

This list will grow over time. Please feel free to suggest new topics.

Instructions for authors (click here to view/hide)